FDA Approves New and Updated Indications for Temozolomide Under Project Renewal

The FDA approved updated labeling for temozolomide (Temodar, Merck) under Project Renewal, an Oncology Center of Excellence initiative aimed at updating labeling information for older oncology drugs to ensure information is clinically meaningful and scientifically up to date. This is the second drug to receive a labeling update under this pilot program. 

Project Renewal is a collaborative program that leverages external oncology experts and early-career scientists to review existing